Can-Fite BioPharma
AboutSciencePipelineInvestor InformationContact Us

About Can-Fite BioPharma

About Us

Overview
Company Leadership
- Management
- Drug Dev. Team
- Board of Directors

 

Management

Pnina Fishman, Ph.D., CEO
Prof. Fishman is the scientific founder of the company and was previously a professor of Life Sciences and headed the Laboratory of Clinical and Tumor Immunology at the Felsenstein Medical Research Institute, Rabin Medical Center. Prof. Fishman is a very accomplished scientist and has authored or co-authored over 150 publications and presented the findings of her research at many major scientific meetings. Her scientific work was the foundation on which Can-Fite was built. This scientific work has gained recognition as one of the leading approaches for new generation therapies for cancer and other diseases. Her past managerial experience included seven years as CEO of Mor Research Application (MRA), a company that was in charge of the commercialization of intellectual property from all hospitals and research centers of Clalit Health Services, the largest healthcare provider in Israel, and was also the first clinical CRO in Israel. She was also involved in the establishment and served on the Board of Directors of several life sciences technology start-ups.
 
Motti Farbstein, CFO
Motti Farbstein past managerial experience included seven years as VP of Mor Research Application (MRA), a company that was in charge of commercialization of intellectual property from all hospitals and research centers of Clalit Health Services, the largest healthcare provider in Israel, and was also the first clinical CRO in Israel. He has extensive experience in data management of clinical trials.
 
Sari Fishman Ph.D., Director Business Development
Dr. Fishman has gained her Ph.D. at the Bar-Ilan University, Ramat-Gan, Israel. She has over 10 years of experience in Clinical Development where she led the regulatory and clinical affairs of Phase I, Phase II and Phase III clinical trials. In addition she conducted all the business development activities  related to the clinical affairs.